March 5, 2024Open Access

Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC

Key Points

Key points are not available for this paper at this time.

Abstract

Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcomes in patients with locally advanced NSCLC.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Hirata et al. (Tue,) studied this question.

synapsesocial.com/papers/68e75a00b6db6435876d0cc8 https://doi.org/https://doi.org/10.1016/j.jtocrr.2024.100659

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions2022 · 33 citations
2Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis2024 · 79 citations
3Cortisol and epinephrine control opposing circadian rhythms in T cell subsets2009 · 358 citations
4Time-of-day infusion of immunotherapy may impact outcomes in advanced non-small cell lung cancer patients (NSCLC).2022 · 12 citations
5A Phase I Study of Recombinant Interferon-α Administered as a Seven-Day Continuous Venous Infusion at Circadian-Rhythm Modulated Rate in Patients with Cancer1995 · 20 citations

Demander à l'IA

Bookmark

View Full Paper